tbuckley/cabot-search huggingface dataset:
L'enquête EUVAC-NET : systèmes de surveillance nationaux de la rougeole dans l'Union européenne, en Suisse, en Norvège et en Islande
Authors: S Glismann, T Ronne, J E Schmidt
Journal: Eurosurveillance (2001)

Le reseau EUVAC-NET a entrepris une etude par questionnaire portant sur les systemes de surveillance de la rougeole dans les pays membres de l’UE, la Suisse, la Norvege et l’Islande. Tous les questionnaires ont ete remplis. Des systemes de surveillance existent dans 16 des 18 pays. La plupart des pays ont des donnees basees sur les cas, ce type de surveillance s’etendant dans tous les pays, bien qu’il existe des differences sur les definitions et les classifications de cas. Un calendrier vaccinal a deux doses de ROR est mis en place dans tous les pays EUVAC-NET mais les methodes utilisees pour evaluer la couverture vaccinale sont variees.
Granulocyte Colony–Stimulating Factor Mobilizes CD34 Cells and Improves Survival of Patients With Decompensated Cirrhosis: A Randomized Controlled Trial
Authors: Ritesh Prajapati, Anil Arora, Praveen Sharma, Naresh Bansal, Vikas Singla, Ashish Kumar
Journal: Clinical Gastroenterology and Hepatology (2016)
HISTORY OF MEDICINE
Authors: H L WECHSLER
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The clinical features of patients with advanced HCC treated with sorafenib who experienced long-term survival
Authors: Koji Sawada, Masami Abe, Yoshinori Saito, Takumu Hasebe, Shunsuke Nakajima, Takaaki Ohtake, Chitomi Hasebe, Mikihiro Fuiya, Yutaka Kohgo
Journal: Annals of Oncology (2015)
Syndesome Therapeutics for Enhancing Diabetic Wound Healing
Authors: Subhamoy Das, Gunjan Singh, Marjan Majid, Michael B. Sherman, Somshuvra Mukhopadhyay, Catherine S. Wright, Patricia E. Martin, Andrew K. Dunn, Aaron B. Baker
Journal: Advanced Healthcare Materials (2016)

Chronic wounds represent a major healthcare and economic problem worldwide. Advanced wound dressings that incorporate bioactive compounds have great potential for improving outcomes in patients with chronic wounds but significant challenges in designing treatments that are effective in long‐standing, nonhealing wounds. Here, an optimized wound healing gel was developed that delivers syndecan‐4 proteoliposomes (“syndesomes”) with fibroblast growth factor‐2 (FGF‐2) to enhance diabetic wound healing. In vitro studies demonstrate that syndesomes markedly increase migration of keratinocytes and fibroblasts isolated from both nondiabetic and diabetic donors. In addition, syndesome treatment leads to increased endocytic processing of FGF‐2 that includes enhanced recycling of FGF‐2 to the cell surface after uptake. The optimized syndesome formulation was incorporated into an alginate wound dressing and tested in a splinted wound model in diabetic, ob/ob mice. It was found that wounds treated with syndesomes and FGF‐2 have markedly enhanced wound closure in comparison to wounds treated with only FGF‐2. Moreover, syndesomes have an immunomodulatory effect on wound macrophages, leading to a shift toward the M2 macrophage phenotype and alterations in the wound cytokine profile. Together, these studies show that delivery of exogenous syndecan‐4 is an effective method for enhancing wound healing in the long‐term diabetic diseased state.
Parallel 8: Novel Molecular Targets in NASH
Authors: Neil Mehta, Julie Heimbach, Denise Harnois, Gonzalo Sapisochin, Jennifer Dodge, David Lee, Justin Burns, William Sanchez, Paul Greig, John Roberts, Francis Yao, Yan Xie, Yang Wu, Jiao-Jing Wang, Hong Xu, Suzanne Ilds- Tad, Zheng Zhang, Josh Levitsky, Suzanne Ildstad, Auvro Mridha, Alexander Wree, Avril Robertson, Narci Teoh, Matthew Cooper, Ariel Feldstein, Geoffrey Farrell
Journal: Hepatology (2015)

may help refine post-LT HCC surveillance strategies and identify patients who would derive the most benefits from future post-LT adjuvant therapies.
Overview: cerebrovascular accident and the hospitalized elderly--a multidimensional clinical problem
Authors: R K Goodstein
Journal: American Journal of Psychiatry (1983)

A cerebrovascular accident is unwelcome at any age, but for the elderly it involves concerns. The abrupt onset of a cerebrovascular accident signals anew the already present fears of loss of control, death, insanity, disfigurement, loss of physical function, and sexual impairment. The accident can also result in worry about the possibility of explosive recurrence, disruption of thoughts and emotions, lengthy treatment away from home, and exhaustion of retirement funds. Therapeutic endeavors must be eclectic and individually tailored to address the special needs of the elderly patient, the highly technical and diverse health care team, the worried family, and the depression, delirium, and subtle clinical syndromes manifesting as poor patient motivation that often accompany a cerebrovascular accident.
Investigating pocket cards to improve cancer patient knowledge of chemotherapy.
Authors: Kelly Kevelin Curtis, Carla M. Johnson, Donald W. Northfelt
Journal: Journal of Clinical Oncology (2012)

35 Background: Studies suggest cancer patients frequently misunderstand information about cancer treatment. Doctors and nurses often give cancer patients written information such as internet-downloaded printouts about chemotherapy. We observed that cancer patients at Mayo Clinic often cannot recall cancer drug names and expected side effects, despite receiving written information. We investigated whether pocket cards [PC] could improve drug name and side effect recall compared to written information alone. Methods: We randomized 100 cancer patients starting chemotherapy to receive PC plus written information or written information alone. Each PC listed the drug name and 3-5 common drug side effects. Written information included a Mayo Clinic produced drug information sheet and printed information from the CareNotes System (Thomson Reuters), with each sheet listing a drug’s name and common side effects. Cancer patients were tested for drug names and side effects recalled at treatment start, again at 4-6 weeks, and again at 8-10 weeks. Results: Of 100 cancer patients randomized (50 to PC plus written information and 50 to written information alone), 66 completed the study. Demographics: median age 64 years (24-81 years); 41 male; 59 female. At 8-10 weeks, no significant difference between groups was observed for drug names recalled correctly (p = 0.79) or median side effects recalled (p = 0.34). Drug name recall declined at 8-10 weeks (29% named drug names correctly at treatment start versus 20% at 8-10 weeks). Median side effects recalled was unchanged at 8-10 weeks (p = 0.19). Conclusions: PC do not appear to improve cancer patients’ drug name recall better that written information alone, nor do PC increase recall of drug side effects. Patient recall of drug names decreases over time. Additional education provided several weeks after chemotherapy has begun may be warranted to reinforce patient knowledge of important treatment-related information.
<i>BRAF</i> Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy
Authors: Sébastien Héritier, Jean-François Emile, Mohamed-Aziz Barkaoui, Caroline Thomas, Sylvie Fraitag, Sabah Boudjemaa, Florence Renaud, Anne Moreau, Michel Peuchmaur, Catherine Chassagne-Clément, Frédérique Dijoud, Valérie Rigau, Despina Moshous, Anne Lambilliotte, Françoise Mazingue, Kamila Kebaili, Jean Miron, Eric Jeziorski, Geneviève Plat, Nathalie Aladjidi, Alina Ferster, Hélène Pacquement, Claire Galambrun, Laurence Brugières, Guy Leverger, Ludovic Mansuy, Catherine Paillard, Anne Deville, Corinne Armari-Alla, Anne Lutun, Marion Gillibert-Yvert, Jean-Louis Stephan, Fleur Cohen-Aubart, Julien Haroche, Isabelle Pellier, Frédéric Millot, Brigitte Lescoeur, Virginie Gandemer, Christine Bodemer, Roger Lacave, Zofia Hélias-Rodzewicz, Valérie Taly, Frédéric Geissmann, Jean Donadieu
Journal: Journal of Clinical Oncology (2016)

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia with a broad spectrum of clinical manifestations and outcomes in children. The somatic BRAF(V600E) mutation occurs frequently, but clinical significance remains to be determined.BRAF(V600E) mutation was investigated in a French LCH cohort. We analyzed associations between mutation status and clinical presentation, extent of disease, reactivation rate, response to therapy, and long-term permanent sequelae.Among 315 patients with successfully determined BRAF status, 173 (54.6%) carried a BRAF(V600E) mutation. Patients with BRAF(V600E) manifested more severe disease than did those with wild-type BRAF. Patients with BRAF(V600E) comprised 87.8% of patients (43 of 49) with multisystem LCH with risk organ involvement (liver, spleen, hematology), 68.6% of patients (35 of 51) with multisystem LCH without risk organ involvement, 43.9% of patients (86 of 196) with single-system LCH, and 42.1% of patients (8 of 19) with lung-involved LCH (P < .001). BRAF(V600E) mutation was also associated with organ involvement that could lead to permanent, irreversible damage, such as neurologic (75%) and pituitary (72.9%) injuries. Compared with patients with wild-type BRAF, patients with BRAF(V600E) more commonly displayed resistance to combined vinblastine and corticosteroid therapy (21.9% v 3.3%; P = .001), showed a higher reactivation rate (5-year reactivation rate, 42.8% v 28.1%; P = .006), and had more permanent, long-term consequences from disease or treatment (27.9% v 12.6%; P = .001).In children with LCH, BRAF(V600E) mutation was associated with high-risk features, permanent injury, and poor short-term response to chemotherapy. Further population-based studies should be undertaken to confirm our observations and to assess the impact of BRAF inhibitors for this subgroup of patients who may benefit from targeted therapy.
Abstract 16002: In Situ Expression of Gsk-3{beta} in Mesenchymal Stem Cells Phase-Dependently Affects the Efficiency of Cell Based Therapy for Chronic Myocardial Infarction
Authors: Jaeyeaon Cho, Peiyong Zhai, Junichi Sadoshima
Journal: Circulation (2010)

Overexpression of glycogen synthase kinase-3β (GSK-3β) in bone marrow derived mesenchymal stem cells (MSCs) enhances the efficiency of cell based therapy (CBT) in the mouse model of myocardial infa...
Large outbreaks of Salmonella Typhimurium infection in Denmark in 2008
Authors: S Ethelberg, A Wingstrand, T Jensen, G Sørensen, L Muller, M Lisby, E M Nielsen, K Mølbak
Journal: Eurosurveillance (2008)

An outbreak of Salmonella Typhimurium phage type U292 has been ongoing in Denmark since 1 April, with 1,054 cases registered until 23 October 2008. Extensive investigations including hypothesis-generating interviews, matched case-control studies, cohort studies in embedded outbreaks, shopping list analyses, analyses of food samples from patient's homes, trace-back analyses and extensive microbiological analysis of products have not provided clear indications of a specific source of infection but the main hypothesis is that the vehicle of the outbreak are different pork products. In addition to the large U292 outbreak, at least four other S. Typhimurium outbreaks (caused by phage types U288, DT120, DT3 and DT135) have been investigated in Denmark in 2008.
Can Administrative Data Assess Physicians' Quality of Care?—Reply
Authors: Scott R Penzak, Edward P Acosta, Michele Turner, Jorge A Tavel, Henry Masur
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Physician-Patient Communication—An Actionable Target for Reducing Overly Aggressive Care Near the End of Life
Authors: Jeffrey D. Robinson, Reshma Jagsi
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 18512: Left Ventricular Diameter Adds Prognostic Value to Ejection Fraction in Risk Stratification for Sudden Cardiac Death
Authors: Kumar Narayanan, Kyndaron Reinier, Carmen Teodorescu, Audrey Uy-Evanado, Harpriya Chugh, Gregory A Nichols, Karen Gunson, Jonathan Jui, Sumeet S Chugh
Journal: Circulation (2013)

Introduction: Current approaches to risk stratification for sudden cardiac death (SCD) rely almost exclusively on the left ventricular (LV) ejection fraction (EF). LV size is routinely measured in the echocardiogram but has not been considered in risk assessment. Hypothesis: We assessed the hypothesis that consideration of LV diameter improves SCD risk assessment in those with low EF. Methods: From a large ongoing, population-based study of SCD in a metro region of the Northwestern US (population approximately 1 million), SCD cases age ≥ 18 years with echocardiograms available prior (but unrelated) to the SCD event were compared with population-based controls. Severe LV dysfunction (LVD) was defined as EF ≤ 35%. LV size, measured using the LV internal dimension in diastole (LVIDD), was categorized as normal, mild, moderate or severe dilatation using American Society of Echocardiography (ASE) recommended cut-offs. Case-control comparisons were performed using the t-test or chi-square test and multiple logistic regression. Results: Case subjects (n=418) were slightly older than controls (n=329) (69.5 ± 13.8 vs. 67.7 ± 11.9; p=0.06), were more likely to be African American (11.8% vs 4.2%; p &lt; 0.001), and more commonly had severe LVD (30.5 % vs. 18.8%; p=0.001). The mean LV size (52.2 ± 10.5 mm vs. 49.7 ± 7.9 mm; p &lt; 0.001 ) and LV size index adjusted for body surface area (BSA) (26.6 ± 5.3 mm/m 2 vs. 25.4 ± 4.2 mm/m 2 ; p = 0.001) were significantly higher in cases. Moderate or severe LV dilatation (16.3% vs. 8.2%; p = 0.001) and severe LV dilatation (8.1% vs. 2.1%; p &lt; 0.001) were significantly more likely to be observed in cases. In multivariable logistic regression, severe LV dilatation was an independent predictor of SCD (OR 2.5; 95% CI 1.03-5.9; p=0.04), adjusting for age, black race and low EF. Subjects with both low EF and severe LV dilatation had an OR for SCD of 3.8 (1.5-10.2) while for those with only low EF, the OR was 1.7 (1.2-2.5) suggesting that severe LV dilatation additively increased the risk of SCD. Conclusions: Increased LV diameter adds incremental prognostic value to LVEF in risk prediction for SCD in the community; this readily available echocardiographic measure warrants further evaluation.
The Carcinogenicity for Mouse Skin and the Aromatic Hydrocarbon Content of Cigarette-Smoke Condensates&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: L ORRIS, B L VAN DUUREN, A I KOSAK, N NELSON, F L SCHMITT
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article The Carcinogenicity for Mouse Skin and the Aromatic Hydrocarbon Content of Cigarette-Smoke Condensates Get access Leo Orris, Leo Orris Institute of Industrial Medicine, New York University-Bellevue Medical Center, New York, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Benjamin L. Van Duuren, Benjamin L. Van Duuren Institute of Industrial Medicine, New York University-Bellevue Medical Center, New York, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Alvin I. Kosak, Alvin I. Kosak Institute of Industrial Medicine, New York University-Bellevue Medical Center, New York, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar Norton Nelson, Norton Nelson Institute of Industrial Medicine, New York University-Bellevue Medical Center, New York, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar F. L. Schmitt F. L. Schmitt Institute of Industrial Medicine, New York University-Bellevue Medical Center, New York, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 21, Issue 3, September 1958, Pages 557–561, https://doi.org/10.1093/jnci/21.3.557 Published: 01 September 1958 Article history Received: 24 March 1958 Published: 01 September 1958
Retrospective study of treatment and outcome for muscle-invasive bladder cancer (MIBC) in Kentucky.
Authors: Justin Allen Williams, Bin Huang, Quan Chen, Peng Wang
Journal: Journal of Clinical Oncology (2016)

e16003 Background: Standard of care for MIBC is neoadjuvant chemotherapy (NACT) and radical cystectomy (RC). This approach remains underutilized despite survival advantage. We evaluate the variable adherence to NACT in different institutions along with different outcome for MIBC in Kentucky. Methods: A retrospective data analysis was performed using the Kentucky Cancer Registry to evaluate patients with MIBC from multiple institutions in KY between years 2004 to 2013. Variables (NACT vs other, or adjuvant (ACT)) and factors (year at diagnosis, age at diagnosis, metro status, smoking status, insurance status, race, stage, tumor grade, and hospital type) were examined. Logistic regression was utilized to identify which factors were associated with the use of NACT. Cox regression and Kaplan-Meier estimate were used to examine which factors impacted survival. SAS 9.4 was used for the statistical analysis. All statistical tests were two sided with a significant level at 0.05. Results: Of 596 patients studied, 19.46% received NACT while 16.44% received ACT and 64.09% received surgery alone. The frequency of NACT increased over 10 years improving from 6.82% in 2004 to 30.88% in 2013 with the largest change occurring between 2007 (3.45%) to 2008 (23.33%). In the logistic regression analysis with the outcome variable NACT vs ACT, year of diagnosis, hospital type, stage and metro status were only significant factors. Patients treated at “Large hospitals” had 2.73 times higher odds of receiving NACT (p = 0.005) and those with stage II had 2.36 times higher odds (p = 0.007). In the Cox regression analysis, age at diagnosis, hospital type, and stage were significantly associated with survival. Old age was associated with higher hazard ratio (p = 0.001); Patients treated at “large hospitals” had better survival than patient treated at “non-large hospitals” (HR = 0.795, p = 0.058); stage II patients had better survival than stage III patients (HR = 0.497, p < 0.001). Lymph nodes (LNs) examined was a protective factor compared to no LNs examined (HR = 0.693, p = 0.006). Conclusions: Higher NACT adherence and quality RC with LNs examined result in better clinical outcome. It is important to identify what barriers limit adherence to NACT in the future.
Geographical Inequalities and Social and Environmental Risk Factors for Under-Five Mortality in Ghana in 2000 and 2010: Bayesian Spatial Analysis of Census Data
Authors: Raphael E. Arku, James E. Bennett, Marcia C. Castro, Kofi Agyeman-Duah, Samilia E. Mintah, James H. Ware, Philomena Nyarko, John D. Spengler, Samuel Agyei-Mensah, Majid Ezzati
Journal: PLoS Medicine (2016)

Under-five mortality is declining in Ghana and many other countries. Very few studies have measured under-five mortality-and its social and environmental risk factors-at fine spatial resolutions, which is relevant for policy purposes. Our aim was to estimate under-five mortality and its social and environmental risk factors at the district level in Ghana.
Paying for bmj.com
Authors: Amelia Johnson, Phaedra Muirhead, Shannon Salisbury, Tanya Stotsky, Carrie Whelan, Kim Yates, Susan Hodges, Jonathan Kotch, Patricia Murphy
Journal: BMJ (2005)

An economic analysis found that an uncomplicated vaginal birth in hospital in the United States cost on average three times as much as a similar birth at home with a midwife. 22Our study of certified professional midwives suggests that they achieve good outcomes among low risk women without routine use of expensive hospital interventions.This evidence supports the American Public Health Association's recommendation 3 to increase access to out of hospital maternity care services with direct entry midwives in the United States.